Chemical Biology and Drug Design

AUGUST 9, 2023

The LC-MS/MS proteomics assay revealed 78 proteins that were differentially expressed upon treatment with plumbagin. Bioinformatics and functional analyses indicated that these proteins were predominantly involved in protein synthesis and translation.

Bioinformatics 100

Bioinformatics Protein Expression Treatment Research 100

Chemical Biology and Drug Design

FEBRUARY 7, 2024

The gene expression of the extracellular matrix was revealed by q-PCR 24 h after IL-1β treatment. We assessed the effect of HSYA and NF-κB signaling pathway-related genes by bioinformatics analysis and conducted molecular docking to assess the interaction of HSYA with a combined protein residue molecule ligand. 10, 40, and 160 μM).

Bioinformatics 100

Bioinformatics Treatment Production Disease 100

Drug Target Review

JUNE 11, 2025

Drug development faces significant challenges: long timelines, high costs , complex processes and low probabilities of success (PoS), exacerbated by the shift towards more complex molecules, biologics and cell and gene therapies, hindering patient access to vital treatments. Highly accurate protein structure prediction for the human proteome.

Drugs 64

Drugs Clinical Trials Drug Development Pharmaceuticals 64

The Open Targets Blog

OCTOBER 31, 2023

Deanne Taylor , lead Principal Investigator of MTP] In the US, formal clinical trials are required to establish the safety and utility of those treatments in pediatric cancers. Clinicians decide on an optimal treatment regimen based on the patient’s cancer subtype.   What was your motivation for creating this resource?

Bioinformatics 65

Bioinformatics Engineering Clinical Trials Therapies 65

ASPET

JANUARY 23, 2024

Moreover, treatment of drug-naïve THP-1 cells with clozapine-exposed EVs induced an inflammasome-dependent response, supporting a potential role for EVs in immune activation. Compared to olanzapine, clozapine induced a greater increase in the concentration of EVs enriched from both cell culture media and rat serum.

Immune Response 100

Immune Response Bioinformatics Regulations Drugs 100

Elrig

MARCH 25, 2025

Prof Rory Johnson is an Associate Professor at University College Dublin, where his research focusses on uncovering the roles of long noncoding RNAs (lncRNAs) in human health and disease using an interdisciplinary combination of bioinformatic and experimental methods.

RNA 59

RNA Bioinformatics Science Pharmacokinetics 59

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. iii Current treatment options have limited efficacy in terms of weight loss or are often associated with adverse events. “We

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

Crown Bioscience

JANUARY 9, 2024

We have published our study on " SynAI " in the journal " Bioinformatics Advances " (November 2023). SynAI is an AI-driven platform designed to predict the synergistic effects of cancer drug combinations, poised to fundamentally change how we discover and evaluate cancer treatments.

Bioinformatics 52

Bioinformatics Drugs Treatment Research 52

Drug Target Review

MARCH 19, 2024

Our polygenic score will enable the application of these treatments to people that specifically need it through precision medicine by identifying the individual at high genetic risk of low circulating levels of the vitamin. The answer is no because there are both genetic and dietary (environmental) causes for low vitamin A.

Laboratories 105

Laboratories Bioinformatics International Research Laboratories 105

The Open Targets Blog

OCTOBER 24, 2023

Amir Feizi is the Director of Bioinformatics at OMass Therapeutics, a spinout from Professor Dame Carol Robinson’s Laboratory at the University of Oxford. OMass Therapeutics is using a new technology platform to develop treatments for rare immunological and genetic diseases with high unmet patient needs.

Bioinformatics 61

Bioinformatics Packaging Pharmaceutical Companies Pharma Companies 61

Drug Target Review

DECEMBER 6, 2024

In cases where control or treatment groups show large variability, this could reflect true biological responses to a treatment, and removing such data could reduce the accuracy of the analysis. It is crucial during this phase to strike a balance between removing erroneous data and preserving meaningful biological variability.

RNA 52

RNA Drugs Research Science 52

The Open Targets Blog

FEBRUARY 29, 2024

  With a background in biochemistry and bioinformatics, Lucy was interested in exploring how bioinformatics was applied to real-world healthcare data. I just graduated with a degree in Bioinformatics, and I was interested to see how the skills I learned could be applied.

International 57

International Bioinformatics RNA Disease 57

Nvidia Developer: Drug Discovery

DECEMBER 19, 2023

HiFi-NN annotates protein sequences with enzyme commission (EC) numbers beating the current bioinformatics tool of choice ( blastp ), as well as other SoTA DL models, including CLEAN , in precision and recall (Table 1).

Science 107

Science Small Molecule Bioinformatics Research 107

The Open Targets Blog

AUGUST 13, 2024

Launched on World IBD Day , this is Open Targets largest project to date and will study the early stages of Inflammatory Bowel Disease (IBD) and treatment at scale, with an amazing team focussed on identifying new and personalised ways to predict, monitor, and treat Crohn’s disease and ulcerative colitis.

Bioinformatics 69

Bioinformatics Disease Treatment Drugs 69

DrugBank

JUNE 5, 2023

Chris Klinger, Scientific Support Lead, Bioinformatics LinkedIn It sounds like there was a lot going on at BioIT, what were your highlights? are a potential wealth of data to understand conditions and treatment responses. There were several excellent presentations on how to use AI/ML/data science to advance drug discovery efforts.

Bioinformatics 98

Bioinformatics Clinical Trials Science Drugs 98

Broad Institute

AUGUST 20, 2024

By Allessandra DiCorato August 20, 2024 Credit: Elizabeth Gribkoff, Eric and Wendy Schmidt Center Yue Qin, a postdoctoral fellow in the Eric and Wendy Schmidt Center, wants to create an in silico cell — a computational model scientists can use to study at scale how external influences such as drug treatments affect cells.

Science 69

Science Bioinformatics Disease Treatment 69

Broad Institute

AUGUST 4, 2022

This profiling could potentially help more accurately tailor prognosis and treatment of a new patient based on their particular molecular features, getting closer to precision medicine."

Bioinformatics 52

Bioinformatics Medical Schools Hospitals Treatment 52

Drug Target Review

MAY 27, 2024

What role do ADCs play in Caris’ strategy for targeted cancer therapy, particularly in terms of patient-specific treatment plans? Patient specific treatment plans can be tailored to the cohorts that express the targets including feasibility assessment of combinations of our ADC targets with other lines of therapy.

Clinical Trials 59

Clinical Trials Science Molecular Biology Bioinformatics 59

Broad Institute

JULY 10, 2023

Alicia Martin and attendees of the KEMRI-Wellcome Trust/GINGER Bioinformatics training in Kilifi, Kenya in September 2018. The program collaborates with academic and research institutions and has been training fellows in bioinformatics, statistics, clinical science, and genetics for the last six years.

Bioinformatics 98

Bioinformatics Disease Medical Schools Research 98

Vial

DECEMBER 5, 2023

Precision medicine and clinical trial design NGS is critical to the development of precision oncology treatment , e.g., targeted therapy, which uses cancer genome profiling to identify the mutation and select the best intervention. This will enable a deeper understanding of cellular processes, disease mechanisms, and personalized treatment.

Clinical Trials 52

Clinical Trials Trials RNA Bioinformatics 52

DrugBank

FEBRUARY 12, 2025

This approach capitalizes on prior investments in R&D, mitigates risk by leveraging established safety and pharmacokinetic profiles, and accelerates the delivery of treatments to patients. In Silico Drug Repurposing Advances in bioinformatics and systems biology have fueled the rise of repurposing of in silico drugs.

Cell Based Assays 52

Cell Based Assays Drugs Pharmacokinetics Disease 52

The Pharma Data

DECEMBER 27, 2020

“This acquisition affirms our commitment to bring a new generation of treatments to patients with pulmonary hypertension as quickly as possible,” said Michael Benkowitz , President and Chief Operating Officer of United Therapeutics. About TYVASO ® (treprostinil) Inhalation Solution. INDICATION.

FDA 52

FDA Bioinformatics Disease Production 52

The Pharma Data

SEPTEMBER 11, 2021

We have the ability to generate precise antibodies to a diverse range of targets, which together with Boehringer Ingelheim’s strength in drug development capabilities, could mean multiple new, more personalized treatments in the future for patients,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist. About Twist Biopharma.

DNA 52

DNA Bioinformatics Production Engineering 52

The Pharma Data

JULY 27, 2021

” The acquisition will also add TNB-585, a Phase 1 bispecific T cell-engager for the treatment of metastatic castrate-resistant prostate cancer (mCRPC), and several preclinical oncology pipeline assets with the potential for near-term IND filings. chief executive officer of Teneobio. ” In June 2021, AbbVie Inc.

Production 52

Production Clinical Trials Government Disease 52

Drug Target Review

SEPTEMBER 26, 2024

This enables us to explore novel drug candidates that could be more effective or have fewer side effects than existing treatments and drugs. Mutlu has a robust academic background that includes a bachelor’s degree in physics, a master’s degree in bioengineering, and a PhD in bioinformatics from the University of Cambridge.

Drugs 64

Drugs Production Research Small Molecule 64

The Pharma Data

OCTOBER 27, 2020

Treatment with Tyvaso of up to 12 breaths per session, four times daily, in the INCREASE study was well tolerated and the safety profile was consistent with previous Tyvaso studies and known prostacyclin-related adverse events. Unituxin in relapsed/refractory neuroblastoma — ANBL1221.

FDA 40

FDA Production Licensing Licensing 40

Chemical Biology and Drug Design

JUNE 11, 2024

Therefore, our research revealed the biological effect of brusatol treatment and provided ATF3 as a novel therapeutic target and prognostic biomarker for HCC therapy. However, the exact mechanism of BRU in the treatment of hepatocellular carcinoma (HCC) remains unknown.

RNA 100

RNA Bioinformatics Treatment Therapies 100

Chemical Biology and Drug Design

NOVEMBER 27, 2023

GO and KEGG enrichment analysis showed A6 treatment mainly disrupted sterol/cholesterol pathway, Ras signaling pathway, VEGF signaling pathway, etc. Moreover, bioinformatic analysis and cell viability test showed A6 plays anticancer role by regulating Best1 and HIST1H2BJ.

Bioinformatics 100

Bioinformatics RNA Regulations Therapies 100

Conversations in Drug Development Trends

APRIL 7, 2025

This variability complicates eligible participant identification and the development of effective treatments, as traditional recruitment methods often result in slow enrollment and high screen-fail rates.

Research 40

Research Clinical Trials Trials Clinical Research 40

Drug Target Review

JULY 24, 2023

The study suggests that this regulatory system could be a potential target for future malaria treatments, offering hope for combatting this deadly disease that affects millions worldwide. With this newfound knowledge, there is renewed hope in the pursuit of effective malaria treatments alleviating the suffering of millions affected.

RNA 98

RNA Regulations Bioinformatics Laboratories 98

The Pharma Data

DECEMBER 8, 2020

9, 2020 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to treprostinil for the treatment of patients with idiopathic pulmonary fibrosis (IPF). SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , INDICATION.

FDA 40

FDA Treatment Drugs FDA Approval 40

The Pharma Data

NOVEMBER 15, 2020

R&D collaboration building on Lead Pharma’s expertise in the discovery, design and optimization of small molecule treatments. “Our ambition is to develop life-changing treatments for patients. Lead Pharma may receive payments of up to €260 million plus royalties on sales. About Lead Pharma.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

Drug Target Review

SEPTEMBER 30, 2024

We see this inhibition of Regulatory T cells (Tregs) in all patients, which is something that no previous IL-2 based treatment has been able to achieve. This is because we designed it to interact with the patient’s own IL-2 in a way that activates cells that attack the tumour, but inhibits cells that protect the tumour.

Bioinformatics 64

Bioinformatics Clinical Trials Clinical Development Treatment 64

The Premier Consulting Blog

JUNE 18, 2023

However, with rare diseases there may be no available treatments that could serve as SoC or active control in a clinical trial and assigning patients to placebo may be unethical. BMC Bioinformatics 2020, 21(Suppl 17):527 [link] Accessed April 4, 2023, at: [link] [2] Russo et al.

Drug Development 52

Drug Development Disease Clinical Trials Drugs 52

Drug Target Review

JUNE 13, 2024

Study co-senior investigator Dr Aristotelis Tsirigos is a professor in the Departments of Pathology and Medicine at NYU Grossman School of Medicine and Perlmutter Cancer Center, where he also is co-director of precision medicine and director of its Applied Bioinformatics Laboratories.

Bioinformatics 45

Bioinformatics Disease Laboratories Hospitals 45

The Pharma Data

OCTOBER 21, 2020

Treatment with Tyvaso of up to 12 breaths per session, four times daily, was well tolerated. Most treatment-related adverse events were mild to moderate in intensity and included cough, headache, dyspnea, dizziness, nausea, fatigue, and diarrhea, many of which are consistent with the existing Tyvaso label. mL and 168.52

Disease 40

Disease Treatment Therapies Production 40

The Pharma Data

JANUARY 21, 2021

Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

Science 40

Science Engineering Molecular Biology Bioinformatics 40